602 related articles for article (PubMed ID: 25913040)
1. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
[TBL] [Abstract][Full Text] [Related]
2. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
[TBL] [Abstract][Full Text] [Related]
3. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
[TBL] [Abstract][Full Text] [Related]
5. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.
Kofler S; Wolf C; Shvets N; Sisic Z; Müller T; Behr J; Sohn HY; Vogeser M; Shipkova M; Meiser B; Steinbeck G; Reichart B; Kaczmarek I
J Heart Lung Transplant; 2011 May; 30(5):565-71. PubMed ID: 21256049
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J
Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients.
Johnston A; He X; Holt DW
Transplantation; 2006 Dec; 82(11):1413-8. PubMed ID: 17164710
[TBL] [Abstract][Full Text] [Related]
9. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients.
Budde K; Bauer S; Hambach P; Hahn U; Röblitz H; Mai I; Diekmann F; Neumayer HH; Glander P
Am J Transplant; 2007 Apr; 7(4):888-98. PubMed ID: 17391132
[TBL] [Abstract][Full Text] [Related]
11. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
Tedesco-Silva H; Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Slade A; Schmouder R; Medina-Pestana JO
Clin Transplant; 2010; 24(4):E116-23. PubMed ID: 20047618
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.
de Winter BC; van Gelder T; Glander P; Cattaneo D; Tedesco-Silva H; Neumann I; Hilbrands L; van Hest RM; Pescovitz MD; Budde K; Mathot RA
Clin Pharmacokinet; 2008; 47(12):827-38. PubMed ID: 19026038
[TBL] [Abstract][Full Text] [Related]
13. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
[TBL] [Abstract][Full Text] [Related]
16. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
[TBL] [Abstract][Full Text] [Related]
17. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
Rath T; Küpper M
Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
[TBL] [Abstract][Full Text] [Related]
18. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N
Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827
[TBL] [Abstract][Full Text] [Related]
20. Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial.
Sunderland A; Russ G; Sallustio B; Cervelli M; Joyce D; Ooi E; Jeffrey G; Boudville N; Chakera A; Dogra G; Chan D; Wong G; Lim WH
Nephrol Dial Transplant; 2020 Jun; 35(6):1060-1070. PubMed ID: 32516810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]